Your browser doesn't support javascript.
loading
Administration of methylene blue in septic shock: pros and cons.
Arias-Ortiz, Julian; Vincent, Jean-Louis.
Afiliação
  • Arias-Ortiz J; Department of Intensive Care, Calderón Guardia Hospital, Universidad de Costa Rica, San José, Costa Rica.
  • Vincent JL; Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles, Route de Lennik 808, Brussels, Belgium. jlvincent@intensive.org.
Crit Care ; 28(1): 46, 2024 02 16.
Article em En | MEDLINE | ID: mdl-38365828
ABSTRACT
Septic shock typically requires the administration of vasopressors. Adrenergic agents remain the first choice, namely norepinephrine. However, their use to counteract life-threatening hypotension comes with potential adverse effects, so that non-adrenergic vasopressors may also be considered. The use of agents that act through different mechanisms may also provide an advantage. Nitric oxide (NO) is the main driver of the vasodilation that leads to hypotension in septic shock, so several agents have been tested to counteract its effects. The use of non-selective NO synthase inhibitors has been of questionable benefit. Methylene blue, an inhibitor of soluble guanylate cyclase, an important enzyme involved in the NO signaling pathway in the vascular smooth muscle cell, has also been proposed. However, more than 25 years since the first clinical evaluation of MB administration in septic shock, the safety and benefits of its use are still not fully established, and it should not be used routinely in clinical practice until further evidence of its efficacy is available.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Choque Séptico / Hipotensão Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Choque Séptico / Hipotensão Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article